Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Antares Pharma, Inc. announced today positive results from its Phase 3 study of Anturol Gel in patients with overactive bladder. The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied.

28 Jul 2010

Female sexual dysfunction can affect quality of life: Research

Almost two-thirds of females attending a general urology practice reported that they suffered from sexual dysfunction, according to a paper in the August issue of BJUI. Dysfunction rose with age in all categories except orgasm, with more than half of women aged from 18 to 30 reporting orgasm problems, significantly higher than women aged 31 to 54.

27 Jul 2010

Underwriters exercise over-allotment option in Uroplasty's common stock public offering

Uroplasty, Inc. announced today that the underwriters for the recently announced public offering of Uroplasty common stock have exercised in full their over-allotment option to purchase an additional 600,000 shares of the Company's common stock. The 4,600,000 shares of Uroplasty common stock in the offering, including the 600,000 shares subject to the over-allotment option, are being sold at a price to the public of $3.50 per share.

26 Jul 2010

Uroplasty prices underwritten public offering of common stock

Uroplasty, Inc. announced today that its underwritten public offering of 4 million shares of its common stock was priced at $3.50 per share. Uroplasty has granted the underwriters of the offering an option to purchase up to an additional 600,000 shares of common stock within the next 30 days, solely to cover over-allotments, if any. All of the shares in the offering are being offered by Uroplasty. Uroplasty expects the offering to close on July 27, 2010, subject to customary closing conditions.

23 Jul 2010

Uroplasty intends to offer shares of common stock in underwritten public offering

Uroplasty, Inc. announced today that it intends, subject to market and other conditions, to offer shares of its common stock in an underwritten public offering. Uroplasty also intends to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any.

22 Jul 2010

SWHR hosts briefing on urinary incontinence, overactive bladder

The Society for Women's Health Research (SWHR) hosted the Capitol Hill briefing, The Bladder Matters: What Women Need to Know on Thursday, July 15, which highlighted startling statistics and an insightful patient perspective. Featuring noted researchers, physicians, Hill staff, and a UI-afflicted patient, the aim of this widely attended briefing was to detail current research on urinary incontinence (UI) and present future outlooks.

22 Jul 2010

EndoStim raises $6M in Series B equity financing round

EndoStim, Inc., a medical device company developing minimally-invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders, today announced it has raised $6 million in Series B equity financing. Santé Ventures, a life science venture capital firm, led the round and was joined by the Prolog Ventures, Vectis Healthcare & Life Sciences Fund II and returning angel investors.

19 Jul 2010

AMS reports positive results from clinical trial of MiniArc Single-Incision Sling System for SUI

American Medical Systems® (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced results of a prospective, multi-center study on their market leading MiniArc Single-Incision Sling System for female stress urinary incontinence (SUI). The study concludes that MiniArc efficacy rates for negative cough stress test (CST) and 1-hr Pad Weight Test (PWT) at 12 months were 90.6 percent and 84.5 percent, respectively.

15 Jul 2010

Diet and exercise can reduce severity of hot flashes in overweight, obese women

A new study shows that overweight and obese women who suffer from hot flashes can reduce the severity of their hot flashes if they lose weight through diet or exercise.

14 Jul 2010

Intensive weight loss intervention program reduces hot flushes in overweight, obese women

Among overweight and obese women with bothersome hot flushes during menopause, an intensive weight loss intervention program may lead to improvements in flushing, according to a report in the July 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Jul 2010

Weight loss related to fewer hot flashes in menopausal women: study

Hot flashes are an uncomfortable and distressing part of menopause that many women go through. Hot flashes also known as hot flushes are usually sudden sweatiness and redness in the face that can remain for four or five years into menopause. Now researchers have shown that losing weight may help reduce these symptoms.

13 Jul 2010

Article related to MN-166 mechanism of action included in PNAS USA

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported that the June 22, 2010 issue of Proceedings of the National Academy of Sciences USA included an article related to the mechanism of action of MN-166 (ibudilast), as an emerging therapeutic for neurological disorders.

8 Jul 2010

Medicare reimbursement rates for outpatient repair of anal fistulas increased by 6%

Hospitals nationwide will receive six percent higher reimbursement payments for outpatient repair of anal fistulas using Cook Medical's Biodesign® Fistula Plug, a device designed specifically to treat this painful and embarrassing disorder of the lower GI tract. According to new Medicare payment schedules effective January 1st, hospital outpatient surgery departments will receive approximately $2,200 per procedure, while freestanding ambulatory surgery centers will be paid about $1,300 on average.

7 Jul 2010

Uroplasty broadens neuromodulation patent portfolio

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,729,772 which covers a method for using an implantable neuromodulation system in the treatment of urinary incontinence by neuromodulation or stimulation of the tibial nerve. The neuromodulation system includes a portable, external transmitter and a receiver implanted subcutaneously in the leg or ankle near the tibial nerve.

1 Jul 2010

FDA grants AMS clearance for MiniArc Precise Single-Incision Sling System

American Medical Systems® (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the Food and Drug Administration (FDA) has cleared the MiniArc® Precise Single-Incision Sling System, a product for the treatment of female stress urinary incontinence (SUI). MiniArc Precise is the next generation sling in the MiniArc family sling system, the number one selling single-incision sling in the United States.

29 Jun 2010

Innovacell Biotechnologie commences enrollment in urocell Phase IIb study for bladder weakness

"First patient in" is the call from the Innsbruck firm, Innovacell Biotechnologie AG, as the first patient was recruited at the MHAT Plovdiv clinic in Bulgaria for the Phase IIb study of the advanced therapy medicinal product, urocell®. The clinical study will be conducted, beside Bulgaria, in the Czech Republic, Germany, Poland and Romania at more than 50 clinics.

15 Jun 2010

Preliminary addition of Uroplasty to Russell Microcap Index

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced it has been included on a list of preliminary additions to the Russell Microcap Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010.

14 Jun 2010

Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Female sexual dysfunction can affect quality of life: Research

Underwriters exercise over-allotment option in Uroplasty's common stock public offering

Uroplasty prices underwritten public offering of common stock

Uroplasty intends to offer shares of common stock in underwritten public offering

SWHR hosts briefing on urinary incontinence, overactive bladder

EndoStim raises $6M in Series B equity financing round

AMS reports positive results from clinical trial of MiniArc Single-Incision Sling System for SUI

Diet and exercise can reduce severity of hot flashes in overweight, obese women

Intensive weight loss intervention program reduces hot flushes in overweight, obese women

Weight loss related to fewer hot flashes in menopausal women: study

Article related to MN-166 mechanism of action included in PNAS USA

Medicare reimbursement rates for outpatient repair of anal fistulas increased by 6%

Uroplasty broadens neuromodulation patent portfolio

FDA grants AMS clearance for MiniArc Precise Single-Incision Sling System

Innovacell Biotechnologie commences enrollment in urocell Phase IIb study for bladder weakness

Preliminary addition of Uroplasty to Russell Microcap Index

Emerging health care models and approaches discussed at 2010 Health Care Conference

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

UT Southwestern researchers compare TVT and TOT sling procedures for stress urinary incontinence

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in